OnCo

Pegylated liposomal doxorubicin

Checked 2026-09-09

Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma

One cycle

every 28 days
1781415212228Pegylated liposomal doxorubicin: 40 mg/m² (20 mg/m² every 2-3 weeks in Kaposi sarcoma), IntravenousPegylated liposomal dox…
28-day cycle, until progressionIntravenous

Components

DrugDoseRouteDays
Pegylated liposomal doxorubicin
Cytotoxic (liposomal anthracycline)
40 mg/m² (20 mg/m² every 2-3 weeks in Kaposi sarcoma)IVD1
Cycles
until progression
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine

Notes

  • Hand-foot syndrome and stomatitis; cardiotoxicity lower than conventional doxorubicin but cumulative dose still counts.

Used in

Source

Gordon, JCO 2001; NCCN Ovarian Cancer

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers